Designing and Advancing Peptide Therapeutics with Purpose
Our therapeutic peptide development programs address some of the most challenging clinical problems.
PLG0206, our lead investigational antibiotic peptide candidate for the treatment of periprosthetic joint infection (PJI), has demonstrated potent in vitro and nonclinical activity, and an acceptable safety profile in healthy volunteers in our Phase I study, supporting a potentially best-in-class profile. PLG0206 is currently being evaluated in patients with PJI in an ongoing clinical trial.
Following our early success in obtaining FDA orphan drug designation for PLG0206 for the treatment of PJI and positive data from our Phase I clinical study, we are expanding our clinical development to additional areas. Based on the inherent properties of peptides, combined with our deep experience and platform capabilities, we have the opportunity to pursue a number of therapeutic areas with significant unmet patient needs.
Watch Craig Della Valle, MD of Midwest Orthopaedics at Rush, discuss the burden of PJI and the potential of PLG02026 to change the treatment paradigm.